Policy Pulse — Global Trade — 06 Jul 2026
🌍 Global Trade Alert: USTR Forced Labor Tariff Hearings, Pharma Tariffs, and Trade Deal Deadlines
Date: 06 Jul 2026 Categories: Tariffs, Trade Deals, Sanctions/Export Controls Tickers impacted (India): SUNPHARMA, DRREDDY, CIPLA, DIVIS, AUROPHARMA, TCS, INFY, WIPRO, HCLTECH, TATASTEEL, JSWSTEEL, WELSPUN, TRIDENT, RAYMOND, PAGEIND, BHARATFORG, INDUSIND, AARTIIND, SRF, GEPIL, CEAT Tickers impacted (US): N/A — Indian policy, Indian stocks only
1. USTR Forced Labor Tariff Hearings — Jul 7-9, 2026
What happened: The U.S. Trade Representative opens public hearings July 7-9 on proposed Section 301 tariffs against 60 economies found to have failed in enforcing forced labor import prohibitions. USTR has proposed 12.5% tariff on over 50 countries including India, with a lower 10% tier for others. The hearings begin tomorrow, with the Section 122 global 10% tariff expiring July 24, 2026.
Key details:
- USTR hearings: July 7-9 (Tue-Thu)
- Current 10% Section 122 tariff expires: July 24
- Replacement: Proposed 12.5% forced labor tariffs (tier 2) on India, China, Vietnam, Thailand, Japan, South Korea + others
- Second probe (structural overcapacity): Still pending — being used as bargaining chip for bilateral deals
- India-US trade deal negotiations ongoing but stalled pending final U.S. tariff plan
- India seeking "comparative advantage" over China, Vietnam, Bangladesh, ASEAN
Irony: The 10% → 12.5% increase may actually benefit Indian exporters vs competitors if it's uniformly applied — India's competitors (Bangladesh, Vietnam, China) would face the same increase. Indian exporters "heave a sigh of relief" per TOI.
Stock Impact — USTR Tariffs
| Stock (India) | Ticker | Impact | Reason |
|---|---|---|---|
| Textiles — Large cap | |||
| Welspun Living | WELSPUN | 🟡 HOLD | Textile exports to US could face 12.5% instead of 10% — manageable increase, but uncertainty over USTR final tier |
| Trident | TRIDENT | 🟡 HOLD | Same as above; home textile exposure to US market |
| Raymond Lifestyle | RAYMOND | 🟢 BUY | Shifting 8% of exports from US to UK/Europe via India-UK CETA; diversification reduces US tariff risk |
| Page Industries | PAGEIND | 🟡 HOLD | Premium innerwear; US exposure limited but sentiment impact |
| Vardhman Textiles | VTL | 🟡 HOLD | Yarn/fabric exports to US; indirect exposure |
| Pharma — Generic exports | |||
| Sun Pharma | SUNPHARMA | 🟢 BUY | Generics EXCLUDED from 100% patented pharma tariffs; Indian generic API exports unaffected |
| Dr Reddy's | DRREDDY | 🟢 BUY | Generics-focused, strong US generic portfolio — no Section 232 impact |
| Divi's Labs | DIVIS | 🟢 BUY | API manufacturer; generics excluded from 100% tariff |
| Cipla | CIPLA | 🟢 BUY | Strong US generics business; no direct tariff hit |
| Aurobindo Pharma | AUROPHARMA | 🟢 BUY | Large US generic portfolio; tariff-immune |
| IT Services | |||
| TCS | TCS | 🟡 HOLD | H-1B visa policy risk remains; tariff uncertainty may delay US client IT spending decisions |
| Infosys | INFY | 🟡 HOLD | Same — US policy uncertainty creates deal-decision drag |
| Metals | |||
| Tata Steel | TATASTEEL | 🟡 HOLD | Steel exports to US already under Section 232; forced labor tariff would stack additional burden |
| JSW Steel | JSWSTEEL | 🟡 HOLD | Same — stacked tariffs = higher landed cost in US |
| Chemicals | |||
| Aarti Industries | AARTIIND | 🟡 HOLD | Chemical intermediates exported to US; tariff layer adds cost |
| SRF | SRF | 🟢 BUY | Specialty chemicals and packaging films; diversified export base reduces single-market risk |
Confidence score: 4/5 — USTR has published proposed rates, hearings are scheduled, timeline is known (Jul 24 deadline)
Source: TOI — USTR probe action creates uncertainty for India
2. US Pharma Tariffs — 100% on Patented Drugs, Generics Excluded
What happened: Trump's April 2, 2026 Section 232 Proclamation imposes 100% ad valorem tariff on imported patented pharmaceutical products and APIs. However, generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded. The tariff took effect July 31, 2026 for 17 named large pharma companies, and September 29, 2026 for all others.
What this means for India:
- India's core pharma export business is overwhelmingly generic — NOT directly affected
- A White House official specifically confirmed generics "shall not be subject to Section 232 tariffs at this time"
- Indian API exporters (Divi's, Aurobindo, Dr Reddy's) to US-bound formulators remain on competitive footing
Stock Impact — US Pharma Tariffs
| Stock (India) | Ticker | Impact | Reason |
|---|---|---|---|
| Divi's Labs | DIVIS | 🟢 BUY | API manufacturer; generics excluded, business as usual for 95%+ of exports |
| Aurobindo Pharma | AUROPHARMA | 🟢 BUY | Large US generics + API; no tariff impact |
| Dr Reddy's | DRREDDY | 🟢 BUY | Generics focused; zero tariff impact |
| Laurus Labs | LAURUS | 🟢 BUY | API + generics; tariff-immune |
| Glenmark | GLENMARK | 🟢 BUY | Generics to US; tariff-exempt category |
| Biocon | BIOCON | 🟢 BUY | Biosimilars excluded; Syngene CRO business unaffected |
Confidence score: 5/5 — Official proclamation text, White House clarification, and legal analysis confirm generics exclusion
Source: Chemox Pharma — US Pharma Tariffs 2026 India
3. USMCA Not Renewed — Annual Reviews Begin
What happened: The Trump administration declined to renew the USMCA trade agreement (Trump's own 2020 replacement for NAFTA). The agreement doesn't expire immediately, but goes into annual reviews with a 10-year clock toward expiration. Effectively, the US is the lone holdout as the agreement continues on autopilot.
Stock impact: Minimal direct India impact. However, it signals continued US unilateralism on trade.
| Stock | Impact | Reason |
|---|---|---|
| Global supply chains | 🟡 HOLD | Continued uncertainty on North American supply chain arrangements |
Confidence: 3/5 — Analysis from trade commentators; no immediate policy change
4. Brazil Tariff Deadline — July 15
What happened: The US has until July 15 to decide whether to impose proposed 25% tariffs on Brazilian goods. Senator Flavio Bolsonaro is lobbying Washington to delay until after Brazil's October election. Exempt products: beef, coffee, rare earths, aircraft parts.
Stock impact: Low direct India impact, but sets precedent for US tariff action against trading partners.
📌 Actionable Ideas — Summary
| Stock | Ticker | Direction | Confidence | Thesis |
|---|---|---|---|---|
| Sun Pharma | SUNPHARMA | 🟢 BUY | 4/5 | Generics tariff-excluded; strong US franchise unfazed |
| Dr Reddy's | DRREDDY | 🟢 BUY | 4/5 | Same thesis; generics immune from 100% pharma tariff |
| Divi's Labs | DIVIS | 🟢 BUY | 4/5 | API maker; generics exclusion protects revenue |
| Raymond Lifestyle | RAYMOND | 🟢 BUY | 3/5 | Diversifying away from US to UK/Europe via CETA; reduces tariff risk |
| SRF | SRF | 🟢 BUY | 3/5 | Diversified exports; less single-market vulnerability |
| Welspun Living | WELSPUN | 🟡 HOLD | 3/5 | US textile exposure; wait for USTR final tier assignment |
| TCS | TCS | 🟡 HOLD | 3/5 | H-1B policy risk; US tariff uncertainty delays IT spending |
| Tata Steel | TATASTEEL | 🟡 HOLD | 3/5 | Already under Section 232; forced labor tariff would stack |
⚠️ Key Dates to Watch
| Date | Event | Impact |
|---|---|---|
| Jul 7-9 | USTR forced labor tariff hearings (~60 countries) | High — tier assignments + effective date |
| Jul 15 | Brazil tariff deadline (25% proposed) | Medium — precedent for USTR enforcement |
| Jul 15 | India-UK CETA effective date | High — zero duty access for Indian exports |
| Jul 24 | Section 122 global 10% tariff expires | High — must be replaced or market disruption |
| Aug 1 | SEBI open market buyback reintroduced | Positive for Indian markets |
| Q3 2026 | USTR final forced labor tariff rule expected | High — actual duty rate + country list |
| Jul 31 | Section 232 100% pharma tariff for named companies | Already priced for named big pharma |
| Sep 29 | Section 232 pharma tariff for all other importers | Watch for potential generics inclusion |
📌 Cumulative Weekly Sector Tilt
| Sector | This Week Signals | Net Direction |
|---|---|---|
| Indian Pharma (Generics) | USTR generics exclusion confirmed; 100% patented tariff doesn't apply | 🟢 Positive |
| Indian Textiles | US forced labor tariff uncertainty vs UK CETA opportunity | 🟡 Mixed |
| Indian IT Services | US tariff uncertainty delays client decisions; H-1B risk overhang | 🟡 Cautious |
| Indian Steel | Stacked tariffs (Section 232 + forced labor) = headwind | 🔴 Negative |
| Indian Chemicals | Diversified exporters better positioned than single-market players | 🟡 Mixed |
Analysis date: 06 Jul 2026 | Sources: USTR, TOI, ET CFO, Bloomberg, Reuters, Chemox Pharma | Confidence scores are indicative, not investment advice